OPERA-02: a phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer ...

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted ...

Though the content of these expressions can be ideologically opposed, each reflects deeper concerns about societal fate, death or the end of a meaningful way of life. Unspoken but underlying is the ...

The center is seeking poster submissions for its annual symposium that relate specifically to this year's theme of using artificial intelligence to redefine the standard of care in medicine ...

CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseasesCAMBRIDGE, Mass., (GLOBE ...

The Company treated the first patient in the pivotal Phase 3 OVATION 3 Study in July 2025 and is working with trial investigators to expand clinical sites and accelerate enrollment. Four sites have ...

Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and ...

Transforming education to prioritise climate resilience and environmental justice is essential for a sustainable future.

Eight patterns emerged for me from the full list of 600 companies. Below are the patterns and lessons for all ...

Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year -- Second pivotal development ...